MET14外显子跳跃突变非小细胞肺癌的治疗现状

doi:10.3760/cma.j.cn371439-20220930-00007

摘要/Abstract

摘要：

MET14外显子（METex14）跳跃突变是非小细胞肺癌（NSCLC）的独立驱动基因。有3%~4%的NSCLC患者携带METex14跳跃突变，此类患者预后差，对于传统化疗、免疫治疗反应欠佳。高选择性MET抑制剂如卡马替尼、特泊替尼、赛沃替尼等在临床试验中显示出良好的有效性及安全性数据，为METex14跳跃突变患者带来新的治疗选择。

关键词: 癌，非小细胞肺, MET14外显子跳跃突变, 分子靶向治疗

Abstract:

MET exon14 （METex14） skipping mutation is an independent driver gene in non-small cell lung cancer （NSCLC）. About 3%-4% of NSCLC patients carry METex14 skipping mutation. These patients have poor prognoses and poor responses to traditional chemotherapy and immunotherapy. Highly selective MET inhibitors such as capmatinib， tepotinib， savolitinib have shown good efficacy and safety data in clinical trials， which bring new treatment options for patients with METex14 skipping mutations.

Key words: Carcinoma， non-small-cell lung, MET exon14 skipping mutation, Molecular targeted therapy

张静娴, 苏剑飞, 卫雪芹, 易丹, 李小江. MET14外显子跳跃突变非小细胞肺癌的治疗现状[J]. 国际肿瘤学杂志, 2023, 50(1): 37-41.

Zhang Jingxian, Su Jianfei, Wei Xueqin, Yi Dan, Li Xiaojiang. Treatment status of non-small cell lung cancer with METexon14 skipping mutation[J]. Journal of International Oncology, 2023, 50(1): 37-41.

参考文献 36

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660. doi: 10.3322/caac.21660
[2]	Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC[J]. Nat Rev Cancer, 2017, 17(11): 637-658. DOI: 10.1038/nrc.2017.84. doi: 10.1038/nrc.2017.84 pmid: 29068003
[3]	Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer[J]. Nat Med, 2021, 27(8): 1345-1356. DOI: 10.1038/s41591-021-01450-2. doi: 10.1038/s41591-021-01450-2 pmid: 34385702
[4]	Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives[J]. Crit Rev Oncol Hematol, 2021, 157: 103194. DOI: 10.1016/j.critrevonc.2020.103194. doi: 10.1016/j.critrevonc.2020.103194
[5]	Bylicki O, Paleiron N, Assié JB, et al. Targeting the MET-signaling pathway in non-small-cell lung cancer: evidence to date[J]. Onco Targets Ther, 2020, 13: 5691-5706. DOI: 10.2147/OTT.S219959. doi: 10.2147/OTT.S219959
[6]	Guo R, Luo J, Chang J, et al. MET-dependent solid tumours—molecular diagnosis and targeted therapy[J]. Nat Rev Clin Oncol, 2020, 17(9): 569-587. DOI: 10.1038/s41571-020-0377-z. doi: 10.1038/s41571-020-0377-z
[7]	Huang C, Zou Q, Liu H, et al. Management of non-small cell lung cancer patients with MET exon 14 skipping mutations[J]. Curr Treat Options Oncol, 2020, 21(4): 33. DOI: 10.1007/s11864-020-0723-5. doi: 10.1007/s11864-020-0723-5
[8]	Zheng Y, Fu Y, Zhong Q, et al. The treatment of advanced pulmonary sarcomatoid carcinoma[J]. Future Oncol, 2022, 18(6): 727-738. DOI: 10.2217/fon-2021-1071. doi: 10.2217/fon-2021-1071
[9]	Cortot AB, Kherrouche Z, Descarpentries C, et al. Exon 14 deleted MET receptor as a new biomarker and target in cancers[J]. J Natl Cancer Inst, 2017, 109(5): djw262. DOI: 10.1093/jnci/djw262. doi: 10.1093/jnci/djw262
[10]	Vuong HG, Ho ATN, Altibi AMA, et al. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer —a systematic review and meta-analysis[J]. Lung Cancer, 2018, 123: 76-82. DOI: 10.1016/j.lungcan.2018.07.006. doi: S0169-5002(18)30464-1 pmid: 30089599
[11]	Bittoni M, Yang JC, Shih JY, et al. Real-world insights into patients with advanced NSCLC and MET alterations[J]. Lung Cancer, 2021, 159: 96-106. DOI: 10.1016/j.lungcan.2021.06.015. doi: 10.1016/j.lungcan.2021.06.015 pmid: 34320421
[12]	Xu Z, Li H, Dong Y, et al. Incidence and PD-L1 expression of MET 14 skipping in Chinese population: a non-selective NSCLC cohort study using RNA-based sequencing[J]. Onco Targets Ther, 2020, 13: 6245-6253. DOI: 10.2147/OTT.S241231. doi: 10.2147/OTT.S241231
[13]	Sabari JK, Leonardi GC, Shu CA, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers[J]. Ann Oncol, 2018, 29(10): 2085-2091. DOI: 10.1093/annonc/mdy334. doi: S0923-7534(19)34207-3 pmid: 30165371
[14]	Kron A, Scheffler M, Heydt C, et al. Genetic heterogeneity of MET-aberrant NSCLC and its impact on the outcome of immunotherapy[J]. J Thorac Oncol, 2021, 16(4): 572-582. DOI: 10.1016/j.jtho.2020.11.017. doi: 10.1016/j.jtho.2020.11.017 pmid: 33309988
[15]	D'Angelo A, Sobhani N, Chapman R, et al. Focus on ROS1-positive non-small cell lung cancer (NSCLC): crizotinib, resistance mechanisms and the newer generation of targeted therapies[J]. Cancers (Basel), 2020, 12(11): 3293. DOI: 10.3390/cancers12113293. doi: 10.3390/cancers12113293
[16]	Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration[J]. Nat Med, 2020, 26(1): 47-51. DOI: 10.1038/s41591-019-0716-8. doi: 10.1038/s41591-019-0716-8 pmid: 31932802
[17]	Moro-Sibilot D, Cozic N, Pérol M, et al. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase Ⅱ trial[J]. Ann Oncol, 2019, 30(12): 1985-1991. DOI: 10.1093/annonc/mdz407. doi: S0923-7534(20)32560-6 pmid: 31987302
[18]	Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer[J]. N Engl J Med, 2020, 383(21): 2018-2029. DOI: 10.1056/NEJMoa2027187. doi: 10.1056/NEJMoa2027187
[19]	Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001[J]. Ann Oncol, 2019, 30(7): 1121-1126. DOI: 10.1093/annonc/mdz131. doi: S0923-7534(19)31237-2 pmid: 31987379
[20]	Reungwetwattana T, Liang Y, Zhu V, et al. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable[J]. Lung Cancer, 2017, 103: 27-37. DOI: 10.1016/j.lungcan.2016.11.011. doi: S0169-5002(16)30527-X pmid: 28024693
[21]	Baltschukat S, Engstler BS, Huang A, et al. Capmatinib (INC280) is active against models of non-small cell lung cancer and other cancer types with defined mechanisms of MET activation[J]. Clin Cancer Res, 2019, 25(10): 3164-3175. DOI: 10.1158/1078-0432.CCR-18-2814. doi: 10.1158/1078-0432.CCR-18-2814 pmid: 30674502
[22]	Wolf J, Seto T, Han JY, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer[J]. N Engl J Med, 2020, 383(10): 944-957. DOI: 10.1056/NEJMoa2002787. doi: 10.1056/NEJMoa2002787
[23]	Mathieu LN, Larkins E, Akinboro O, et al. FDA approval summary: capmatinib and tepotinib for the treatment of metastatic NSCLC harboring MET exon 14 skipping mutations or alterations[J]. Clin Cancer Res, 2022, 28(2): 249-254. DOI: 10.1158/1078-0432.CCR-21-1566. doi: 10.1158/1078-0432.CCR-21-1566
[24]	Markham A. Tepotinib: first approval[J]. Drugs, 2020, 80(8): 829-833. DOI: 10.1007/s40265-020-01317-9. doi: 10.1007/s40265-020-01317-9 pmid: 32361823
[25]	Lai GGY, Guo R, Drilon A, et al. Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision[J]. Cancer Treat Rev, 2022, 110: 102444. DOI: 10.1016/j.ctrv.2022.102444. doi: 10.1016/j.ctrv.2022.102444
[26]	Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations[J]. N Engl J Med, 2020, 383(10): 931-943. DOI: 10.1056/NEJMoa2004407. doi: 10.1056/NEJMoa2004407
[27]	Le X, Sakai H, Felip E, et al. Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: outcomes in patient subgroups from the VISION study with relevance for clinical practice[J]. Clin Cancer Res, 2022, 28(6): 1117-1126. DOI: 10.1158/1078-0432.CCR-21-2733. doi: 10.1158/1078-0432.CCR-21-2733
[28]	Tanaka H, Taima K, Makiguchi T, et al. Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation[J]. Cancer Commun (Lond), 2021, 41(1): 83-87. DOI: 10.1002/cac2.12124. doi: 10.1002/cac2.12124
[29]	Lu S, Fang J, Li X, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study[J]. Lancet Respir Med, 2021, 9(10): 1154-1164. DOI: 10.1016/S2213-2600(21)00084-9. doi: 10.1016/S2213-2600(21)00084-9 pmid: 34166627
[30]	Ai J, Chen Y, Peng X, et al. Preclinical evaluation of SCC244 (glumetinib), a novel, potent, and highly selective inhibitor of c-Met in MET-dependent cancer models[J]. Mol Cancer Ther, 2018, 17(4): 751-762. DOI: 10.1158/1535-7163.MCT-17-0368. doi: 10.1158/1535-7163.MCT-17-0368 pmid: 29237805
[31]	ClinicalTrials. gov. A phase Ⅰb/Ⅱ, open-label, multicenter study to evaluate the efficacy and safety of glumetinib (SCC244), a selective MET inhibitor in patients with advanced non-small cell lung cancer harboring MET-alterations[EB/OL]. [2019-07-15] [2022-09-07]. https://clinicaltrials.gov/ct2/show/NCT04270591.
[32]	Lu S, Yu Y, Zhou J, et al. Abstract CT034: phase Ⅱ study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study)[J]. Cancer Res, 2022, 82(12_Supplement): CT034. DOI: 10.1158/1538-7445.AM2022-CT034. doi: 10.1158/1538-7445.AM2022-CT034
[33]	Neijssen J, Cardoso RMF, Chevalier KM, et al. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET[J]. J Biol Chem, 2021, 296: 100641. DOI: 10.1016/j.jbc.2021.100641. doi: 10.1016/j.jbc.2021.100641
[34]	Vyse S, Huang PH. Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer[J]. Expert Rev Anticancer Ther, 2022, 22(1): 3-16. DOI: 10.1080/14737140.2022.2016397. doi: 10.1080/14737140.2022.2016397
[35]	ClinicalTrials. gov. A phase 1, first-in-human, open-label, dose escalation study of JNJ-61186372, a human bispecific EGFR and cMet antibody, in subjects with advanced non-small cell lung cancer[EB/OL]. [2016-05-24] [2022-09-07]. https://clinicaltrials.gov/ct2/show/NCT02609776?term=NCT02609776&draw=2&rank=1.
[36]	Amivantamab emerges positively from its "Chrysalis"[J]. Cancer Discov, 2022, 12(8): OF2. DOI: 10.1158/2159-8290.CD-NB2022-0044. doi: 10.1158/2159-8290.CD-NB2022-0044